238 related articles for article (PubMed ID: 22419578)
1. Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.
Gowin K; Thapaliya P; Samuelson J; Harrison C; Radia D; Andreasson B; Mascarenhas J; Rambaldi A; Barbui T; Rea CJ; Camoriano J; Gentry A; Kiladjian JJ; O'Connell C; Mesa R
Haematologica; 2012 Oct; 97(10):1570-3. PubMed ID: 22419578
[TBL] [Abstract][Full Text] [Related]
2. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative neoplasms treated with hydroxyurea, pegylated interferon alpha-2A or ruxolitinib: clinicohematologic responses, quality-of-life changes and safety in the real-world setting.
Gill H; Leung GMK; Yim R; Lee P; Pang HH; Ip HW; Leung RYY; Li J; Panagiotou G; Ma ESK; Kwong YL
Hematology; 2020 Dec; 25(1):247-257. PubMed ID: 32567517
[No Abstract] [Full Text] [Related]
4. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
Masarova L; Patel KP; Newberry KJ; Cortes J; Borthakur G; Konopleva M; Estrov Z; Kantarjian H; Verstovsek S
Lancet Haematol; 2017 Apr; 4(4):e165-e175. PubMed ID: 28291640
[TBL] [Abstract][Full Text] [Related]
6. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
Them NC; Bagienski K; Berg T; Gisslinger B; Schalling M; Chen D; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Zagrijtschuk O; Klade C; Greil R; Gisslinger H; Kralovics R
Am J Hematol; 2015 Apr; 90(4):288-94. PubMed ID: 25545244
[TBL] [Abstract][Full Text] [Related]
7. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
Mascarenhas J; Kosiorek H; Prchal J; Yacoub A; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Salama ME; Weinberg RS; Rampal R; Goldberg JD; Mesa R; Dueck AC; Hoffman R
Leukemia; 2019 Dec; 33(12):2974-2978. PubMed ID: 31363161
[No Abstract] [Full Text] [Related]
8. Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.
Ianotto JC; Chauveau A; Boyer-Perrard F; Gyan E; Laribi K; Cony-Makhoul P; Demory JL; de Renzis B; Dosquet C; Rey J; Roy L; Dupriez B; Knoops L; Legros L; Malou M; Hutin P; Ranta D; Benbrahim O; Ugo V; Lippert E; Kiladjian JJ
Haematologica; 2018 Mar; 103(3):438-446. PubMed ID: 29217781
[TBL] [Abstract][Full Text] [Related]
9. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
Stein BL; Tiu RV
J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.
Ianotto JC; Boyer-Perrard F; Gyan E; Laribi K; Cony-Makhoul P; Demory JL; De Renzis B; Dosquet C; Rey J; Roy L; Dupriez B; Knoops L; Legros L; Malou M; Hutin P; Ranta D; Schoenwald M; Andreoli A; Abgrall JF; Kiladjian JJ
Br J Haematol; 2013 Sep; 162(6):783-91. PubMed ID: 23848933
[TBL] [Abstract][Full Text] [Related]
11. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.
Kucine N; Bergmann S; Krichevsky S; Jones D; Rytting M; Jain J; Bennett CM; Resar LMS; Mascarenhas J; Verstovsek S; Hoffman R
Pediatr Blood Cancer; 2021 Mar; 68(3):e28888. PubMed ID: 33381905
[TBL] [Abstract][Full Text] [Related]
12. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Papaemmanuil E; Salama M; Singer-Weinberg R; Rampal R; Goldberg JD; Barbui T; Mesa R; Dueck AC; Hoffman R
Blood; 2019 Oct; 134(18):1498-1509. PubMed ID: 31515250
[TBL] [Abstract][Full Text] [Related]
13. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
Alsaran K; Sabry A; Shaheen N
Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
[TBL] [Abstract][Full Text] [Related]
14. Highlights in myeloproliferative neoplasms from the 60th American Society of Hematology Annual Meeting.
Clin Adv Hematol Oncol; 2019 Jan; 17 Suppl 2(1):1-20. PubMed ID: 31545309
[No Abstract] [Full Text] [Related]
15. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series.
Beauverd Y; Radia D; Cargo C; Knapper S; Drummond M; Pillai A; Harrison C; Robinson S
Haematologica; 2016 May; 101(5):e182-4. PubMed ID: 26819057
[No Abstract] [Full Text] [Related]
16. Essential thrombocythaemia treated with recombinant interferon: 'real world' United Kingdom referral centre experience.
Desterro J; McLornan DP; Curto Garcia N; O'Sullivan J; Alimam S; Keohane C; Woodley C; Francis Y; Kordasti S; Radia DH; Harrison CN
Br J Haematol; 2019 Aug; 186(4):561-564. PubMed ID: 31090926
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Ropeginterferon Alfa-2B in High-Risk Patients with Philadelphia Chromosome Negative Myeloproliferative Neoplasms- Evaluation of Clinicohaematologic Response, and Safety Profile: Single Centre Experience.
Popova-Labachevska M; Cvetanoski M; Ridova N; Trajkova S; Stojanovska-Jakimovska S; Mojsovska T; Stojanoski Z; Pivkova-Veljanovska A; Panovska-Stavridis I
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2023 Dec; 44(3):57-62. PubMed ID: 38109450
[No Abstract] [Full Text] [Related]
18. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
[TBL] [Abstract][Full Text] [Related]
19. Reversible bone marrow aplasia induced by pegylated interferon-α-2a therapy in a patient with primary myelofibrosis.
Mainali NR; Bhatt VR; Kedia S; Krishnamurthy J; Wake LM; Akhtari M
J Oncol Pharm Pract; 2014 Oct; 20(5):386-92. PubMed ID: 24067929
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
Hüsken AC; Tsianakas A; Hensen P; Nashan D; Loquai C; Beissert S; Luger TA; Sunderkötter C; Schiller M
J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]